Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CRVS 
Corvus Pharmaceuticals Inc (CRVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: CRVS (3-star) is a STRONG-BUY. BUY since 22 days. Simulated Profits (21.24%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.75
1 Year Target Price $15.75
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 992.49% | Avg. Invested days 30 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 434.42M USD | Price to earnings Ratio - | 1Y Target Price 15.75 |
Price to earnings Ratio - | 1Y Target Price 15.75 | ||
Volume (30-day avg) 6 | Beta 0.51 | 52 Weeks Range 2.54 - 10.00 | Updated Date 09/15/2025 |
52 Weeks Range 2.54 - 10.00 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.85% | Return on Equity (TTM) -68.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 361092847 | Price to Sales(TTM) - |
Enterprise Value 361092847 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.36 | Shares Outstanding 74514000 | Shares Floating 57356436 |
Shares Outstanding 74514000 | Shares Floating 57356436 | ||
Percent Insiders 3.96 | Percent Institutions 56.24 |
Upturn AI SWOT
Corvus Pharmaceuticals Inc
Company Overview
History and Background
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel medicines designed to harness the immune system to treat cancer. It was founded in 2002. Key milestones include clinical trials for its lead product candidate, CPI-444, and strategic partnerships with larger pharmaceutical companies.
Core Business Areas
- Oncology Drug Development: Focuses on developing novel therapies that target the immune system to fight cancer. Their primary focus is on adenosine pathway inhibitors and other immuno-oncology approaches.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. The organizational structure includes research and development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- CPI-818: An investigational ITK inhibitor being developed for T cell lymphomas. Currently in Phase 3 trials. No market share or revenue data available as it's pre-commercialization. Competitors include companies developing other T cell lymphoma therapies such as Kyowa Kirin with Poteligeo, and Seagen with Adcetris.
- CPI-006: An anti-CD73 antibody designed to block the production of adenosine in the tumor microenvironment. Currently in clinical development. No market share or revenue data is available. Competitors include AstraZeneca which has an anti-CD73 in clinical trials.
- CPI-444 (Adenosine A2A Receptor Antagonist): Formerly the lead drug. No longer the primary focus as clinical trials have been discontinued or deprioritized in certain indications. No market share or revenue data available.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and regulatory scrutiny. The immuno-oncology segment is experiencing rapid growth due to the success of checkpoint inhibitors and other immune-based therapies.
Positioning
Corvus Pharmaceuticals is a clinical-stage company focused on developing novel immuno-oncology therapies. Its competitive advantage lies in its targeting of the adenosine pathway.
Total Addressable Market (TAM)
The total addressable market for immuno-oncology therapies is estimated to be in the tens of billions of dollars. Corvus is targeting niche areas within this larger market, focusing on specific tumor types and patient populations.
Upturn SWOT Analysis
Strengths
- Novel immuno-oncology approach (adenosine pathway)
- Experienced management team
- Proprietary drug candidates
- Focus on specific patient populations with unmet needs
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Reliance on clinical trial success
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Breakthrough Therapy designation from regulatory agencies
Threats
- Clinical trial failures
- Competition from established immuno-oncology therapies
- Regulatory hurdles
- Financing challenges
Competitors and Market Share
Key Competitors
- KYWA
- MRK
- AZN
Competitive Landscape
Corvus faces significant competition from established pharmaceutical companies with approved immuno-oncology therapies. Its competitive advantage lies in its novel approach and focus on specific patient populations, but it is a smaller player in a crowded field.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced growth in research and development spending as it advances its clinical programs.
Future Projections: Future growth is dependent on the success of clinical trials and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include enrolling patients in Phase 3 trials for CPI-818 and advancing preclinical programs.
Summary
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company with a novel approach to immuno-oncology, targeting the adenosine pathway. Its success hinges on positive clinical trial results, particularly for CPI-818. The company faces significant competition and financial challenges. Successful partnerships and regulatory approvals are crucial for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Corvus Pharmaceuticals Inc. SEC Filings
- Company Website
- Analyst Reports (where available)
- Market Research Reports (where available)
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual risk tolerance and financial circumstances. Market share data is estimated and may not be precise. Financial data is as available, and may be outdated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Corvus Pharmaceuticals Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2016-03-23 | Co-Founder, President, CEO & Chairman of the Board Dr. Richard A. Miller M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 31 | Website https://www.corvuspharma.com |
Full time employees 31 | Website https://www.corvuspharma.com | ||
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.